Company news: Genzyme, inVentiv

Share this article:
Genzyme said it agreed to sell its genetic testing business to LabCorp for $925 million in cash, roughly three times the unit's 2009 revenue. Jefferies analyst Eun Yang said the sale of Genzyme Genetics does not change the course of the biotech firm's potential to be bought. The company recently rejected Sanofi-Aventis' $18.5-billion takeover offer, or $69 a share. Two other business units are also on the block—the diagnostic products and pharmaceutical intermediates businesses—under a five-part plan Genzyme announced in May to increase shareholder value that also includes cost-cutting. The Boston Globe put the number of layoffs expected at the Cambridge, MA, firm at 1,000 employees worldwide over 15 months. More details of the cost-cutting are expected later this week.

InVentiv is merging Irvine, CA-based medical advertising shop Ignite Health with Manhattan-based Y Brand, a healthcare branding and strategy firm. Y Brand will remain in Manhattan as a division of Ignite Health, and president Vince Perry will become chief branding officer for Ignite Health
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.